Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
immunoglobulin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subcutaneous immunoglobulin | ACTIVE_COMPARATOR | - |
| Saline | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Subcutaneous immunoglobulin | DRUG | The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place. |
Inclusion Criteria: * All patients with typical or pure motor CIDP, who meet the clinical or electrophysiological criteria of the EFNS/PNS for certain or probable CIDP and who are in regular treatment with IVIg on one of the neurological departments in Denmark, are eligible for the study Exclusion...
Immunoglobulin is being studied for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a neurological condition. It is administered subcutaneously and is currently in Phase 2 clinical development as an investigational therapy for this indication.
Immunoglobulin is being developed by Baxter International Inc., a company traded on the New York Stock Exchange under the ticker symbol BAX. The company is conducting clinical research on this therapy for chronic inflammatory demyelinating polyradiculoneuropathy.
Immunoglobulin is in Phase 2 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. A Phase 2 clinical trial for this drug has been completed, involving 30 participants with chronic inflammatory demyelinating polyradiculoneuropathy.
Immunoglobulin has one completed clinical trial, registered as NCT01017159, titled "Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)." This Phase 2 study enrolled 30 participants in Denmark and was a randomized, double-blind, placebo-controlled trial.
Immunoglobulin is administered subcutaneously in the clinical trial for chronic inflammatory demyelinating polyradiculoneuropathy. The study specifically evaluates subcutaneous immunoglobulin treatment, and the drug is referred to as immunoglobulin in the trial registration.